Supernus Pharmaceuticals, INC 10-Q quarterly reports

Supernus Pharmaceuticals, Inc. reported a net loss of $58.4 million for the second quarter of 2026, impacted by a $54.9 million impairment charge, while total revenues increased 32% year-over-year.

Supernus Pharmaceuticals reported a significant net loss in Q3 2025, driven by the Sage Therapeutics acquisition and increased expenses, despite strong sales growth for Qelbree and the launch of ONAPGO.

Supernus Pharmaceuticals reports a significant drop in Q2 2025 net earnings and operating income, despite strong growth in key products and a major acquisition.

Supernus Pharmaceuticals' Q1 2025 results show increased revenue driven by Qelbree and GOCOVRI, offset by declines in other products, and the launch of ONAPGO.

Supernus Pharmaceuticals saw a significant increase in revenue and profitability in Q3 2024, driven by strong sales of Qelbree and GOCOVRI, while also advancing its pipeline with a resubmitted NDA for SPN-830.

Supernus Pharmaceuticals saw a significant increase in net product sales, particularly driven by Qelbree, in the second quarter of 2024, while also advancing its pipeline with a resubmitted NDA for SPN-830.

Supernus Pharmaceuticals experienced a slight decrease in total revenue for Q1 2024, while advancing its clinical pipeline and receiving a Complete Response Letter for SPN-830.